Suppression of mammary hyperplastic nodule formation and pituitary prolactin secretion in mice induced by ergocornine or 2-bromo-a-ergocryptine.
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004876:Ergot Alkaloids / Q000627:therapeutic use*; D004971:Estrus / Q000187:drug effects; D005260:Female; D013006:Growth Hormone / Q000378:metabolism*; D006965:Hyperplasia; D008321:Mammary Glands, Animal / Q000187:drug effects* / Q000473:pathology; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D051379:Mice; D009929:Organ Size; D010053:Ovary / Q000187:drug effects; D010902:Pituitary Gland / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D011230:Precancerous Conditions; D011247:Pregnancy; D011388:Prolactin / Q000378:metabolism*; D014599:Uterus / Q000187:drug effects
D004876:Ergot Alkaloids; D011388:Prolactin; D013006:Growth Hormone